▶ 調査レポート

世界の抗肥満薬市場 2021:企業別、地域別、種類・用途別

• 英文タイトル:Global Anti-obesity Medicine Market 2021 by Company, Regions, Type and Application, Forecast to 2026

GlobalInfoResearchが調査・発行した産業分析レポートです。世界の抗肥満薬市場 2021:企業別、地域別、種類・用途別 / Global Anti-obesity Medicine Market 2021 by Company, Regions, Type and Application, Forecast to 2026 / GIR-107A14918資料のイメージです。• レポートコード:GIR-107A14918
• 出版社/出版日:GlobalInfoResearch / 2021年7月
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、91ページ
• 納品方法:Eメール(納期:2~3日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥515,040 (USD3,480)▷ お問い合わせ
  Multi User¥772,560 (USD5,220)▷ お問い合わせ
  Corporate User¥1,030,080 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料では、抗肥満薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。抗肥満薬の種類別市場規模(処方薬、OTC薬)、用途別市場規模(男性、女性)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・抗肥満薬の市場概要
・企業情報(企業概要、製品概要、販売量、価格、売上):Alizyme、Amylin Pharmaceuticals、Arena Pharmaceuticals、Boehringer Ingelheim、Eisai、GlaxoSmithKline、Orexigen Therapeutics、Vivus、Pfizer、Roche、Merck、Novo Nordisk
・企業別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年:処方薬、OTC薬
・用途別分析2016年-2026年:男性、女性
・抗肥満薬の北米市場規模2016年-2026年:アメリカ、カナダ、メキシコ
・抗肥満薬のヨーロッパ市場規模2016年-2026年:ドイツ、イギリス、フランス、ロシア、イタリア
・抗肥満薬のアジア市場規模2016年-2026年:中国、日本、韓国、インド、東南アジア、オーストラリア
・抗肥満薬の南米市場規模2016年-2026年:ブラジル、アルゼンチン
・抗肥満薬の中東・アフリカ市場規模2016年-2026年:サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Anti-obesity Medicine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Anti-obesity Medicine size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Anti-obesity Medicine market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Anti-obesity Medicine market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Prescription Drugs
OTC Drugs

Market segment by Application, can be divided into
Men
Women

Market segment by players, this report covers
Alizyme
Amylin Pharmaceuticals
Arena Pharmaceuticals
Boehringer Ingelheim
Eisai
GlaxoSmithKline
Orexigen Therapeutics
Vivus
Pfizer
Roche
Merck
Novo Nordisk

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Anti-obesity Medicine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Anti-obesity Medicine, with revenue, gross margin and global market share of Anti-obesity Medicine from 2019 to 2021.
Chapter 3, the Anti-obesity Medicine competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Anti-obesity Medicine market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Anti-obesity Medicine research findings and conclusion, appendix and data source.

レポート目次

1 Market Overview
1.1 Product Overview and Scope of Anti-obesity Medicine
1.2 Classification of Anti-obesity Medicine by Type
1.2.1 Overview: Global Anti-obesity Medicine Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Anti-obesity Medicine Revenue Market Share by Type in 2020
1.2.3 Prescription Drugs
1.2.4 OTC Drugs
1.3 Global Anti-obesity Medicine Market by Application
1.3.1 Overview: Global Anti-obesity Medicine Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Men
1.3.3 Women
1.4 Global Anti-obesity Medicine Market Size & Forecast
1.5 Global Anti-obesity Medicine Market Size and Forecast by Region
1.5.1 Global Anti-obesity Medicine Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Anti-obesity Medicine Market Size by Region, (2016-2021)
1.5.3 North America Anti-obesity Medicine Market Size and Prospect (2016-2026)
1.5.4 Europe Anti-obesity Medicine Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Anti-obesity Medicine Market Size and Prospect (2016-2026)
1.5.6 South America Anti-obesity Medicine Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Anti-obesity Medicine Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Anti-obesity Medicine Market Drivers
1.6.2 Anti-obesity Medicine Market Restraints
1.6.3 Anti-obesity Medicine Trends Analysis
2 Company Profiles
2.1 Alizyme
2.1.1 Alizyme Details
2.1.2 Alizyme Major Business
2.1.3 Alizyme Anti-obesity Medicine Product and Solutions
2.1.4 Alizyme Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Alizyme Recent Developments and Future Plans
2.2 Amylin Pharmaceuticals
2.2.1 Amylin Pharmaceuticals Details
2.2.2 Amylin Pharmaceuticals Major Business
2.2.3 Amylin Pharmaceuticals Anti-obesity Medicine Product and Solutions
2.2.4 Amylin Pharmaceuticals Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Amylin Pharmaceuticals Recent Developments and Future Plans
2.3 Arena Pharmaceuticals
2.3.1 Arena Pharmaceuticals Details
2.3.2 Arena Pharmaceuticals Major Business
2.3.3 Arena Pharmaceuticals Anti-obesity Medicine Product and Solutions
2.3.4 Arena Pharmaceuticals Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Arena Pharmaceuticals Recent Developments and Future Plans
2.4 Boehringer Ingelheim
2.4.1 Boehringer Ingelheim Details
2.4.2 Boehringer Ingelheim Major Business
2.4.3 Boehringer Ingelheim Anti-obesity Medicine Product and Solutions
2.4.4 Boehringer Ingelheim Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Boehringer Ingelheim Recent Developments and Future Plans
2.5 Eisai
2.5.1 Eisai Details
2.5.2 Eisai Major Business
2.5.3 Eisai Anti-obesity Medicine Product and Solutions
2.5.4 Eisai Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Eisai Recent Developments and Future Plans
2.6 GlaxoSmithKline
2.6.1 GlaxoSmithKline Details
2.6.2 GlaxoSmithKline Major Business
2.6.3 GlaxoSmithKline Anti-obesity Medicine Product and Solutions
2.6.4 GlaxoSmithKline Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 GlaxoSmithKline Recent Developments and Future Plans
2.7 Orexigen Therapeutics
2.7.1 Orexigen Therapeutics Details
2.7.2 Orexigen Therapeutics Major Business
2.7.3 Orexigen Therapeutics Anti-obesity Medicine Product and Solutions
2.7.4 Orexigen Therapeutics Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Orexigen Therapeutics Recent Developments and Future Plans
2.8 Vivus
2.8.1 Vivus Details
2.8.2 Vivus Major Business
2.8.3 Vivus Anti-obesity Medicine Product and Solutions
2.8.4 Vivus Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Vivus Recent Developments and Future Plans
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer Anti-obesity Medicine Product and Solutions
2.9.4 Pfizer Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Pfizer Recent Developments and Future Plans
2.10 Roche
2.10.1 Roche Details
2.10.2 Roche Major Business
2.10.3 Roche Anti-obesity Medicine Product and Solutions
2.10.4 Roche Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Roche Recent Developments and Future Plans
2.11 Merck
2.11.1 Merck Details
2.11.2 Merck Major Business
2.11.3 Merck Anti-obesity Medicine Product and Solutions
2.11.4 Merck Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Merck Recent Developments and Future Plans
2.12 Novo Nordisk
2.12.1 Novo Nordisk Details
2.12.2 Novo Nordisk Major Business
2.12.3 Novo Nordisk Anti-obesity Medicine Product and Solutions
2.12.4 Novo Nordisk Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Novo Nordisk Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Anti-obesity Medicine Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Anti-obesity Medicine Players Market Share
3.2.2 Top 10 Anti-obesity Medicine Players Market Share
3.2.3 Market Competition Trend
3.3 Anti-obesity Medicine Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Anti-obesity Medicine Revenue and Market Share by Type (2016-2021)
4.2 Global Anti-obesity Medicine Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Anti-obesity Medicine Revenue Market Share by Application (2016-2021)
5.2 Anti-obesity Medicine Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Anti-obesity Medicine Revenue by Type (2016-2026)
6.2 North America Anti-obesity Medicine Revenue by Application (2016-2026)
6.3 North America Anti-obesity Medicine Market Size by Country
6.3.1 North America Anti-obesity Medicine Revenue by Country (2016-2026)
6.3.2 United States Anti-obesity Medicine Market Size and Forecast (2016-2026)
6.3.3 Canada Anti-obesity Medicine Market Size and Forecast (2016-2026)
6.3.4 Mexico Anti-obesity Medicine Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Anti-obesity Medicine Revenue by Type (2016-2026)
7.2 Europe Anti-obesity Medicine Revenue by Application (2016-2026)
7.3 Europe Anti-obesity Medicine Market Size by Country
7.3.1 Europe Anti-obesity Medicine Revenue by Country (2016-2026)
7.3.2 Germany Anti-obesity Medicine Market Size and Forecast (2016-2026)
7.3.3 France Anti-obesity Medicine Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Anti-obesity Medicine Market Size and Forecast (2016-2026)
7.3.5 Russia Anti-obesity Medicine Market Size and Forecast (2016-2026)
7.3.6 Italy Anti-obesity Medicine Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Anti-obesity Medicine Revenue by Type (2016-2026)
8.2 Asia-Pacific Anti-obesity Medicine Revenue by Application (2016-2026)
8.3 Asia-Pacific Anti-obesity Medicine Market Size by Region
8.3.1 Asia-Pacific Anti-obesity Medicine Revenue by Region (2016-2026)
8.3.2 China Anti-obesity Medicine Market Size and Forecast (2016-2026)
8.3.3 Japan Anti-obesity Medicine Market Size and Forecast (2016-2026)
8.3.4 South Korea Anti-obesity Medicine Market Size and Forecast (2016-2026)
8.3.5 India Anti-obesity Medicine Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Anti-obesity Medicine Market Size and Forecast (2016-2026)
8.3.7 Australia Anti-obesity Medicine Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Anti-obesity Medicine Revenue by Type (2016-2026)
9.2 South America Anti-obesity Medicine Revenue by Application (2016-2026)
9.3 South America Anti-obesity Medicine Market Size by Country
9.3.1 South America Anti-obesity Medicine Revenue by Country (2016-2026)
9.3.2 Brazil Anti-obesity Medicine Market Size and Forecast (2016-2026)
9.3.3 Argentina Anti-obesity Medicine Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Anti-obesity Medicine Revenue by Type (2016-2026)
10.2 Middle East & Africa Anti-obesity Medicine Revenue by Application (2016-2026)
10.3 Middle East & Africa Anti-obesity Medicine Market Size by Country
10.3.1 Middle East & Africa Anti-obesity Medicine Revenue by Country (2016-2026)
10.3.2 Turkey Anti-obesity Medicine Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Anti-obesity Medicine Market Size and Forecast (2016-2026)
10.3.4 UAE Anti-obesity Medicine Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Anti-obesity Medicine Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Anti-obesity Medicine Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Anti-obesity Medicine Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Anti-obesity Medicine Revenue (USD Million) by Region (2016-2021)
Table 5. Global Anti-obesity Medicine Revenue Market Share by Region (2021-2026)
Table 6. Alizyme Corporate Information, Head Office, and Major Competitors
Table 7. Alizyme Major Business
Table 8. Alizyme Anti-obesity Medicine Product and Solutions
Table 9. Alizyme Anti-obesity Medicine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Amylin Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 11. Amylin Pharmaceuticals Major Business
Table 12. Amylin Pharmaceuticals Anti-obesity Medicine Product and Solutions
Table 13. Amylin Pharmaceuticals Anti-obesity Medicine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Arena Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 15. Arena Pharmaceuticals Major Business
Table 16. Arena Pharmaceuticals Anti-obesity Medicine Product and Solutions
Table 17. Arena Pharmaceuticals Anti-obesity Medicine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors
Table 19. Boehringer Ingelheim Major Business
Table 20. Boehringer Ingelheim Anti-obesity Medicine Product and Solutions
Table 21. Boehringer Ingelheim Anti-obesity Medicine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Eisai Corporate Information, Head Office, and Major Competitors
Table 23. Eisai Major Business
Table 24. Eisai Anti-obesity Medicine Product and Solutions
Table 25. Eisai Anti-obesity Medicine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 27. GlaxoSmithKline Major Business
Table 28. GlaxoSmithKline Anti-obesity Medicine Product and Solutions
Table 29. GlaxoSmithKline Anti-obesity Medicine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Orexigen Therapeutics Corporate Information, Head Office, and Major Competitors
Table 31. Orexigen Therapeutics Major Business
Table 32. Orexigen Therapeutics Anti-obesity Medicine Product and Solutions
Table 33. Orexigen Therapeutics Anti-obesity Medicine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Vivus Corporate Information, Head Office, and Major Competitors
Table 35. Vivus Major Business
Table 36. Vivus Anti-obesity Medicine Product and Solutions
Table 37. Vivus Anti-obesity Medicine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Pfizer Corporate Information, Head Office, and Major Competitors
Table 39. Pfizer Major Business
Table 40. Pfizer Anti-obesity Medicine Product and Solutions
Table 41. Pfizer Anti-obesity Medicine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Roche Corporate Information, Head Office, and Major Competitors
Table 43. Roche Major Business
Table 44. Roche Anti-obesity Medicine Product and Solutions
Table 45. Roche Anti-obesity Medicine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Merck Corporate Information, Head Office, and Major Competitors
Table 47. Merck Major Business
Table 48. Merck Anti-obesity Medicine Product and Solutions
Table 49. Merck Anti-obesity Medicine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Novo Nordisk Corporate Information, Head Office, and Major Competitors
Table 51. Novo Nordisk Major Business
Table 52. Novo Nordisk Anti-obesity Medicine Product and Solutions
Table 53. Novo Nordisk Anti-obesity Medicine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Global Anti-obesity Medicine Revenue (USD Million) by Players (2019-2021)
Table 55. Global Anti-obesity Medicine Revenue Share by Players (2019-2021)
Table 56. Breakdown of Anti-obesity Medicine by Company Type (Tier 1, Tier 2 and Tier 3)
Table 57. Anti-obesity Medicine Players Head Office, Products and Services Provided
Table 58. Anti-obesity Medicine Mergers & Acquisitions in the Past Five Years
Table 59. Anti-obesity Medicine New Entrants and Expansion Plans
Table 60. Global Anti-obesity Medicine Revenue (USD Million) by Type (2016-2021)
Table 61. Global Anti-obesity Medicine Revenue Share by Type (2016-2021)
Table 62. Global Anti-obesity Medicine Revenue Forecast by Type (2021-2026)
Table 63. Global Anti-obesity Medicine Revenue by Application (2016-2021)
Table 64. Global Anti-obesity Medicine Revenue Forecast by Application (2021-2026)
Table 65. North America Anti-obesity Medicine Revenue by Type (2016-2021) & (USD Million)
Table 66. North America Anti-obesity Medicine Revenue by Type (2021-2026) & (USD Million)
Table 67. North America Anti-obesity Medicine Revenue by Application (2016-2021) & (USD Million)
Table 68. North America Anti-obesity Medicine Revenue by Application (2021-2026) & (USD Million)
Table 69. North America Anti-obesity Medicine Revenue by Country (2016-2021) & (USD Million)
Table 70. North America Anti-obesity Medicine Revenue by Country (2021-2026) & (USD Million)
Table 71. Europe Anti-obesity Medicine Revenue by Type (2016-2021) & (USD Million)
Table 72. Europe Anti-obesity Medicine Revenue by Type (2021-2026) & (USD Million)
Table 73. Europe Anti-obesity Medicine Revenue by Application (2016-2021) & (USD Million)
Table 74. Europe Anti-obesity Medicine Revenue by Application (2021-2026) & (USD Million)
Table 75. Europe Anti-obesity Medicine Revenue by Country (2016-2021) & (USD Million)
Table 76. Europe Anti-obesity Medicine Revenue by Country (2021-2026) & (USD Million)
Table 77. Asia-Pacific Anti-obesity Medicine Revenue by Type (2016-2021) & (USD Million)
Table 78. Asia-Pacific Anti-obesity Medicine Revenue by Type (2021-2026) & (USD Million)
Table 79. Asia-Pacific Anti-obesity Medicine Revenue by Application (2016-2021) & (USD Million)
Table 80. Asia-Pacific Anti-obesity Medicine Revenue by Application (2021-2026) & (USD Million)
Table 81. Asia-Pacific Anti-obesity Medicine Revenue by Region (2016-2021) & (USD Million)
Table 82. Asia-Pacific Anti-obesity Medicine Revenue by Region (2021-2026) & (USD Million)
Table 83. South America Anti-obesity Medicine Revenue by Type (2016-2021) & (USD Million)
Table 84. South America Anti-obesity Medicine Revenue by Type (2021-2026) & (USD Million)
Table 85. South America Anti-obesity Medicine Revenue by Application (2016-2021) & (USD Million)
Table 86. South America Anti-obesity Medicine Revenue by Application (2021-2026) & (USD Million)
Table 87. South America Anti-obesity Medicine Revenue by Country (2016-2021) & (USD Million)
Table 88. South America Anti-obesity Medicine Revenue by Country (2021-2026) & (USD Million)
Table 89. Middle East & Africa Anti-obesity Medicine Revenue by Type (2016-2021) & (USD Million)
Table 90. Middle East & Africa Anti-obesity Medicine Revenue by Type (2021-2026) & (USD Million)
Table 91. Middle East & Africa Anti-obesity Medicine Revenue by Application (2016-2021) & (USD Million)
Table 92. Middle East & Africa Anti-obesity Medicine Revenue by Application (2021-2026) & (USD Million)
Table 93. Middle East & Africa Anti-obesity Medicine Revenue by Country (2016-2021) & (USD Million)
Table 94. Middle East & Africa Anti-obesity Medicine Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Anti-obesity Medicine Picture
Figure 2. Global Anti-obesity Medicine Revenue Market Share by Type in 2020
Figure 3. Prescription Drugs
Figure 4. OTC Drugs
Figure 5. Anti-obesity Medicine Revenue Market Share by Application in 2020
Figure 6. Men Picture
Figure 7. Women Picture
Figure 8. Global Anti-obesity Medicine Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 9. Global Anti-obesity Medicine Revenue and Forecast (2016-2026) & (USD Million)
Figure 10. Global Anti-obesity Medicine Revenue Market Share by Region (2016-2026)
Figure 11. Global Anti-obesity Medicine Revenue Market Share by Region in 2020
Figure 12. North America Anti-obesity Medicine Revenue (USD Million) and Growth Rate (2016-2026)
Figure 13. Europe Anti-obesity Medicine Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Asia-Pacific Anti-obesity Medicine Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. South America Anti-obesity Medicine Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Middle East and Africa Anti-obesity Medicine Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Anti-obesity Medicine Market Drivers
Figure 18. Anti-obesity Medicine Market Restraints
Figure 19. Anti-obesity Medicine Market Trends
Figure 20. Alizyme Recent Developments and Future Plans
Figure 21. Amylin Pharmaceuticals Recent Developments and Future Plans
Figure 22. Arena Pharmaceuticals Recent Developments and Future Plans
Figure 23. Boehringer Ingelheim Recent Developments and Future Plans
Figure 24. Eisai Recent Developments and Future Plans
Figure 25. GlaxoSmithKline Recent Developments and Future Plans
Figure 26. Orexigen Therapeutics Recent Developments and Future Plans
Figure 27. Vivus Recent Developments and Future Plans
Figure 28. Pfizer Recent Developments and Future Plans
Figure 29. Roche Recent Developments and Future Plans
Figure 30. Merck Recent Developments and Future Plans
Figure 31. Novo Nordisk Recent Developments and Future Plans
Figure 32. Global Anti-obesity Medicine Revenue Share by Players in 2020
Figure 33. Anti-obesity Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 34. Global Top 3 Players Anti-obesity Medicine Revenue Market Share in 2020
Figure 35. Global Top 10 Players Anti-obesity Medicine Revenue Market Share in 2020
Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 37. Global Anti-obesity Medicine Revenue Share by Type in 2020
Figure 38. Global Anti-obesity Medicine Market Share Forecast by Type (2021-2026)
Figure 39. Global Anti-obesity Medicine Revenue Share by Application in 2020
Figure 40. Global Anti-obesity Medicine Market Share Forecast by Application (2021-2026)
Figure 41. North America Anti-obesity Medicine Sales Market Share by Type (2016-2026)
Figure 42. North America Anti-obesity Medicine Sales Market Share by Application (2016-2026)
Figure 43. North America Anti-obesity Medicine Revenue Market Share by Country (2016-2026)
Figure 44. United States Anti-obesity Medicine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Anti-obesity Medicine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Anti-obesity Medicine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Anti-obesity Medicine Sales Market Share by Type (2016-2026)
Figure 48. Europe Anti-obesity Medicine Sales Market Share by Application (2016-2026)
Figure 49. Europe Anti-obesity Medicine Revenue Market Share by Country (2016-2026)
Figure 50. Germany Anti-obesity Medicine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. France Anti-obesity Medicine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. United Kingdom Anti-obesity Medicine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Russia Anti-obesity Medicine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Italy Anti-obesity Medicine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Asia-Pacific Anti-obesity Medicine Sales Market Share by Type (2016-2026)
Figure 56. Asia-Pacific Anti-obesity Medicine Sales Market Share by Application (2016-2026)
Figure 57. Asia-Pacific Anti-obesity Medicine Revenue Market Share by Region (2016-2026)
Figure 58. China Anti-obesity Medicine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Japan Anti-obesity Medicine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. South Korea Anti-obesity Medicine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. India Anti-obesity Medicine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Southeast Asia Anti-obesity Medicine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Australia Anti-obesity Medicine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South America Anti-obesity Medicine Sales Market Share by Type (2016-2026)
Figure 65. South America Anti-obesity Medicine Sales Market Share by Application (2016-2026)
Figure 66. South America Anti-obesity Medicine Revenue Market Share by Country (2016-2026)
Figure 67. Brazil Anti-obesity Medicine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Argentina Anti-obesity Medicine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Middle East and Africa Anti-obesity Medicine Sales Market Share by Type (2016-2026)
Figure 70. Middle East and Africa Anti-obesity Medicine Sales Market Share by Application (2016-2026)
Figure 71. Middle East and Africa Anti-obesity Medicine Revenue Market Share by Country (2016-2026)
Figure 72. Turkey Anti-obesity Medicine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Saudi Arabia Anti-obesity Medicine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. UAE Anti-obesity Medicine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Methodology
Figure 76. Research Process and Data Source